General, MS News Tysabri: reducing the risk of PML with extended interval dosing Written by Ellen on December 12th, 2019December 8th, 2021. Tysabri (natalizumab) is very effective for people with highly active relapsing remitting MS but it carries the risk of developing a rare but very serious brain infection called progressive multifocal […]